As presented at EHA 2026, AGAVE-201 showed no significant bone health safety signals with axatilimab in chronic graft-versus-host disease (cGVHD).
Amandeep Salhotra
Advertisement
Amandeep Salhotra, MD, is a hematologist-oncologist and an associate professor at City of Hope.
Articles by Amandeep Salhotra
The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis
2
Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course
3
Small Workflow Changes Close Big Gaps in CKM Screening
4
Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care
5